Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection

Phase 3

• Conditions: Bleeding Esophageal Varices
• Interventions: Drug: Injection Sclerotherapy; Drug: N-butyl-2-cyanoacrylate

• Registration Number: NCT03388125
• Lead Sponsor: Sherief Abd-Elsalam

Brief Summary

Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate Injection

Detailed Description

Endoscopic Injection Sclerotherapy versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices

Study Timeline

• Study Start: 2016-01-01
• Primary Completion: 2017-08-01
• Study First Submitted: 2017-12-23
• Study First Submitted QC: 2017-12-23
• Study First Posted: 2018-01-02
• Status Verified: 2018-04
• Last Update Submitted: 2018-04-20
• Last Update Posted: 2018-04-24
• Study Completion: 2022-12-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 113

Inclusion Criteria

• cirrhotic patients presented with actively bleeding

Exclusion Criteria

• other sources of UGIB than esophageal varices, hepatic encephalopathy or hepatocellular carcinoma (HCC)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Injection Sclerotherapy	Injection Sclerotherapy	5% ethano lamine oleate
N-butyl-2-cyanoacrylate	N-butyl-2-cyanoacrylate	N-butyl-2-cyanoacrylate injection group

Primary Outcome Measures

Name	Time	Method
Number of patients with controlled bleeding	6 months	The Number of patients with controlled bleeding

Trial Locations

Locations (1)

Sherief Abd-Elsalam; 🇪🇬 Tanta, Egypt